Zion Pharma
Hong Kong, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $40M
Overview
A clinical-stage Chinese biotech developing novel small molecule oncology drugs using DMPK-driven design for best-in-class and first-in-class candidates.
Oncology
Technology Platform
A drug discovery platform centered on leveraging DMPK (Drug Metabolism and Pharmacokinetics) expertise to rationally design small molecule drugs with optimized properties for oncology.
Opportunities
Opportunities include successfully advancing ZN-A-1041 through clinical trials, leveraging its DMPK platform to build a robust pipeline of novel oncology assets, and forming strategic partnerships with larger pharmaceutical companies for development and commercialization.
Risk Factors
Key risks include clinical trial failure of its lead candidate, high competition in the oncology drug development space, and execution risks associated with managing a growing pipeline and organization.
Competitive Landscape
Zion Pharma competes with numerous other Chinese and global biotechs in oncology small molecule drug discovery. Its stated differentiation is a focus on DMPK-driven design to create drugs with potentially best-in-class profiles, but it must demonstrate clinical validation.